SATURDAY, MAY 24, 2025
9:10 am – 9:30 am

New Treatments In PBC

Learning Objectives:

• Understand when to consider 2nd line therapies in PBC.
• Review the evidence for 2nd line therapies addressing disease activity in PBC.
• Review therapies for cholestatic itch in PBC. 

Speaker:

Dr. Kristel Leung, MD, FRCPC, PhD candidate, BSc (Hons)

Kingston Health Sciences Centre
Queen’s University, Department of Medicine, Division of Gastroenterology

Dr. Kristel Leung is an Assistant Professor of Medicine in the Division of Gastroenterology at Queen's University. She completed medical school at the University of British Columbia, Internal Medicine residency in Ottawa, and Gastroenterology fellowship in Toronto. She then pursued two years of advanced clinical and research fellowship in autoimmune liver disease, followed by work as a clinical associate hepatologist at the Toronto Centre for Liver Disease. Dr. Leung is also completing a PhD in Clinical Epidemiology and Health Care Research at the University of Toronto as a CIHR Vanier Canada Graduate Scholar. Her research focuses on advanced statistical methods to evaluate epidemiology, outcomes, and patient-reported symptom burden in autoimmune cholestatic liver diseases. With experience working with ICES-linked administrative data, detailed cohort datasets, and patient-reported outcomes, Dr. Leung is particularly interested in integrating multi-level data to answer patient-centred clinical questions in autoimmune liver disease and decompensated cirrhosis.